{"id":"NCT02636595","sponsor":"AbbVie","briefTitle":"The Efficacy and Safety of ABT-493/ABT-530 in Adults With Chronic Hepatitis C Virus Genotype 4, 5, or 6 Infection (ENDURANCE-4)","officialTitle":"A Single-Arm, Open-Label Study to Evaluate the Efficacy and Safety of ABT-493/ABT-530 in Adults With Chronic Hepatitis C Virus Genotype 4, 5, or 6 Infection (ENDURANCE-4)","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2015-11","primaryCompletion":"2016-10","completion":"2017-01","firstPosted":"2015-12-22","resultsPosted":"2017-09-14","lastUpdate":"2021-07-13"},"enrollment":121,"design":{"allocation":"NA","model":"SINGLE_GROUP","masking":"NONE","primaryPurpose":"TREATMENT"},"conditions":["Hepatitis C Virus"],"interventions":[{"type":"DRUG","name":"ABT-493/ABT-530","otherNames":["ABT-493 also known as glecaprevir","ABT-530 also known as pibrentasvir","MAVYRET"]}],"arms":[{"label":"ABT-493/ABT-530","type":"EXPERIMENTAL"}],"summary":"The purpose of this study is to evaluate the effect of response to treatment by evaluating the percentage of subjects achieving a 12-week sustained virologic response (SVR12) after 12 weeks of treatment with ABT-493/ABT-530 and to evaluate the safety of the regimen in participants with chronic hepatitis C virus (HCV) genotype (GT) 4, 5, or 6 infection.","primaryOutcome":{"measure":"Percentage of Participants With Sustained Virologic Response 12 Weeks Post-treatment (SVR12)","timeFrame":"12 weeks after the last actual dose of study drug","effectByArm":[{"arm":"ABT-493/ABT-530","deltaMin":99.2,"sd":null}],"pValues":[]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":null,"exclusionCount":null},"locations":{"siteCount":0,"countries":[]},"refs":{"pmids":["28951228","31568620","30977945","30923816","30529905","30012435"],"seeAlso":["http://rxabbvie.com"]},"adverseEventsSummary":{"seriousAny":{"events":1,"n":121},"commonTop":["HEADACHE","FATIGUE","NAUSEA","ASTHENIA","PRURITUS"]}}